Bridging Innovators: Wallonia-UK Advanced Therapies Mission 2024

30 Sept – 3 Oct 2024 | United Kingdom

Benjamin DAMIEN

CEO

SAGITTA BIOTECH

Liège, Liège, Belgium

6 profile visitsWalloon Participant

Sagitta Biotech is a company developing vaccines from an innovative plaftorm. We are able to develop vaccines able to answer most unmet medical needs.

About me

Phd in Immunology and MBA from Solvay.
Managing Biotech companies since 2003.

My organisation

Sagitta Biotech is developing innovative therapies against infectious diseases and cancer based on its viral vector/mRNA platform.

Sagitta's innovative platform is based on a reverse-engineering of the Measles virus, able to express up to 6 different antigen on its surface (including affinity proteins to infect cells carrying specific markers) and to deliver a self-replicating RNA in the cells.

The technology is being used to develop multivalent vaccines, oncology products or gene therapy vectors. We are looking for partners to evaluate our technology as a way to modify cells in vitro or in vivo (CAR T cell generation in vivo).

Social media

Skills

  • vaccines
  • Immunology
  • oncology
  • Molecular Biology
  • Management
  • corporate funding

Interests

  • Funding
  • deal making
  • startups

Marketplace (1)